Manipulating proglucagon processing in the pancreatic alpha-cell for the treatment of diabetes
Glucagon-like peptide-1 (GLP-1) has received much attention as a novel diabetes therapeutic due to its pleotropic blood glucose-lowering effects, including enhancement of glucose-stimulated insulin secretion, inhibition of gastric emptying and glucagon secretion, and promotion of beta-cell survival...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | en |
| Published: |
University of British Columbia
2007
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/2429/222 |